دورية أكاديمية
أعرض في EDS

High prevalence of MAFLD in general population: A large cross-sectional study calls for concerted public health action.

التفاصيل البيبلوغرافية
العنوان: High prevalence of MAFLD in general population: A large cross-sectional study calls for concerted public health action.
المؤلفون: Prabhakar T; Department of Clinical Research and Epidemiology, Institute of Liver and Biliary Sciences, New Delhi, India., Prasad M; Department of Clinical Research and Epidemiology, Institute of Liver and Biliary Sciences, New Delhi, India., Kumar G; Department of Biostatistics, Institute of Liver and Biliary Sciences, New Delhi, India., Kaushal K; Department of Clinical Research and Epidemiology, Institute of Liver and Biliary Sciences, New Delhi, India., Shenoy PS; Department of Clinical Research and Epidemiology, Institute of Liver and Biliary Sciences, New Delhi, India., Dubey S; Assistant Head Operations, Institute of Liver and Biliary Sciences, New Delhi, India., Sarin SK; Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
المصدر: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2024 Apr; Vol. 59 (7), pp. 843-851. Date of Electronic Publication: 2024 Feb 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Wiley-Blackwell
Original Publication: [Oxford, OX] : Blackwell Scientific Publications, [c1987-
مواضيع طبية MeSH: Public Health* , Liver Cirrhosis*/epidemiology, Male ; Humans ; Female ; Adult ; Middle Aged ; Prevalence ; Cross-Sectional Studies ; Obesity/complications ; Obesity/epidemiology
مستخلص: Background: Metabolic associated fatty liver disease (MAFLD) is a relatively new term with limited studies done in South Asian population.
Aim: To determine prevalence and clinico-epidemiological characteristics of MAFLD in general population.
Methods: A cross-sectional study was conducted in randomly selected regions across Delhi, India. Data were collected on socio-demographic particulars, health status and lifestyle factors. Anthropometric measurements, transient elastography, and laboratory investigations were carried out.
Results: Altogether 6146 participants (mean age: 43.1 ± 13.9 years, 48.1% males) were included. The prevalence of MAFLD was 56.4% (n = 3468), of which lean MAFLD constituted 11.3%. Higher age (OR: 2.47; 95% CI: 2.21-2.76), low education level (OR: 1.23; 95% CI: 1.09-1.39), upper socio-economic class (OR: 1.32; 95% CI: 1.17-1.49), and low physical activity (OR: 1.15; 95% CI: 1.03-1.28) were more common in MAFLD. The association of female sex with MAFLD differed in age groups <40 years (OR: 0.64 and 95% CI: 0.55-0.75) and >40 years (OR: 1.40 and 95% CI: 1.22-1.62) in both magnitude and direction (p < 0.001). Liver fibrosis was present in 23% of the study population (32.2% among MAFLD group). Advanced liver fibrosis was three times more common in MAFLD group (6.2% vs 1.8%, p < 0.001). Obesity and fibrosis had a statistically significant relationship and 75.8% of the individuals with advanced stages of fibrosis had obesity.
Conclusion: Nearly half of study population was found to have MAFLD. Advanced hepatic fibrosis was three times more common in these subjects. Aggressive public health measures are urgently required to raise awareness and introduce interventional strategies.
(© 2024 John Wiley & Sons Ltd.)
التعليقات: Comment in: Aliment Pharmacol Ther. 2024 Apr;59(7):900-901. doi: 10.1111/apt.17903. (PMID: 38462698)
References: Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an inter-national expert consensus statement. J Hepatol. 2020;73:202-209.
Inoue Y, Qin B, Poti J, Sokol R, Gordon-Larsen P. Epidemiology of obesity in adults: latest trends. Curr Obes Rep. 2018;7:276-288.
Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
Elhence A, Bansal B, Gupta H, Anand A, Singh TP, Goel A. Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis. J Clin Exp Hepatol. 2022;12(3):818-829.
Wong VWS, Vergniol J, Wong GLH, Foucher J, Chan HLY, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454-462.
Goff DC Jr, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, et al. Dyslipidemia prevalence, treatment, and control in the multi-ethnic study of atherosclerosis (MESA). Circulation. 2006;113(5):647-656.
Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030.
Standards of medical Care in Diabetes-2016: summary of revisions. Diabetes Care. 2016;39(Suppl 1):S4-S5.
Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009;57:163-170.
Hagströmer M, Oja P, Sjöström M. The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr. 2006;9(6):755-762.
Pentapati SSK, Debnath DJ. Updated BG Prasad's classification for the year 2022. J Family Med Prim Care. 2023;12(1):189-190. https://doi.org/10.4103/jfmpc.jfmpc&#95;1478&#95;22.
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel; Chair; EASL Governing Board representative; Panel members. EASL clinical practice guidelines (CpGs) on non-invasive tests for evaluation of liver disease severity and Prognosis-2021 update. J Hepatol. 2021;75:689.
Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology and Hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5:167-228.
Wong MC, Huang JL, George J, Huang J, Leung C, Eslam M, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16:57-73.
Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389-398.
Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51:1593-1602.
Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol. 2007;6:161-163.
Chalmers J, Ban L, Leena KB, Edwards KL, Grove JL, Aithal GP, et al. Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort. BMJ Open. 2019;9(5):e027244.
Mahajan R, Duseja A, Kumar R, Chakraborti A, Lakshmi PV. A community-based study to determine the prevalence of nonalcoholic fatty liver disease (NAFLD) and its metabolic risk factors in urban and rural communities of north India. J Gastroenterol Hepatol. 2019;34(suppl 3):310.
Chen Y-L, Li H, Li S, Xu Z, Tian S, Wu J, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 2021;21:212.
Eslam M, Sanyal AJ, George J, International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1.
Ylse GG, Guadalupe PR, Ramos MH, Uribe M, Méndez-Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, postmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol. 2010;9:402-409.
Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151-171.
Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519-1523.
Wu Y, Zheng Q, Zou B, Yeo YH, Li X, Li J, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatol Int. 2020;14(2):259-269. https://doi.org/10.1007/s12072-020-10023-3.
Barker DJ. Fetal origins of coronary heart disease. Br Med J. 1995;311(6998):171-174.
Forsdahl A. Living conditions in childhood and subsequent development of risk factors for arteriosclerotic heart disease. The cardiovascular survey in Finmark 1974-75. J Epidemiol Community Health. 1978;32(1):34-37.
Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017;12(3):e0173499. https://doi.org/10.1371/journal.pone.0173499.
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11-20.
Feng R-N, Du S-S, Wang C, Li Y-C, Liu L-Y, Guo F-C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol. 2014;20:17932-17940.
Yuan Q, Wang H, Gao P, Chen W, Lv M, Bai S, et al. Prevalence and risk factors of metabolic-associated fatty liver disease among 73,566 individuals in Beijing, China. Int J Environ Res Public Health. 2022;19(4):2096.
Semmler G, Wernly S, Bachmayer S, Wernly B, Schwenoha L, Huber-Schönauer U, et al. Nonalcoholic fatty liver disease in lean subjects: associations with metabolic dysregulation and cardiovascular risk-a single-center cross-sectional study. Clin Transl Gastroenterol. 2021;12:e00326.
van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H. The effects of physical exercise on fatty liver disease. Gene Expr. 2018;18(2):89-101.
von Loeffelholz C, Roth J, Coldewey SM, Birkenfeld AL. The role of physical activity in nonalcoholic and metabolic dysfunction associated fatty liver disease. Biomedicine. 2021;9(12):1853.
Widmer CC, Pereira CP, Gehrig P, Vallelian F, Schoedon G, Buehler PW, et al. Hemoglobin can attenuate hydrogen peroxide-induced oxidative stress by acting as an antioxidative peroxidase. Antioxid Redox Signal. 2010;12:185-198.
Bai CH, Wu MS, Owaga E, Cheng SY, Pan WH, Chang JS. Relationship between hemoglobin levels and risk for suspected non-alcoholic fatty liver in Taiwanese adults. Chin J Physiol. 2014;57:286-294.
Rastogi A, Manthey J, Wiemker V, Probst C. Alcohol consumption in India: a systematic review and modelling study for sub-national estimates of drinking patterns. Addiction. 2022;117:1871-1886.
Sarin SK, Prasad M, Ramalingam A, Kapil U. Integration of public health measures for NAFLD into India's national programme for NCDs. Lancet Gastroenterol Hepatol. 2021;6(10):777-778.
فهرسة مساهمة: Keywords: India; MAFLD; NAFLD; epidemiology; fatty liver; lean
تواريخ الأحداث: Date Created: 20240207 Date Completed: 20240312 Latest Revision: 20240710
رمز التحديث: 20240710
DOI: 10.1111/apt.17892
PMID: 38321716
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-2036
DOI:10.1111/apt.17892